Metronomia Clinical Research
Metronomia Clinical Research is recorded as a service provider in 29 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 29 trials · Latest update first
Phase 1/2a Open-Label, Dose-Escalation, Multicenter, First-in-Human, Consecutive-Cohort, Clinical Trial of BI-1910, a Monoclonal Antibody to Tumor Necrosis Factor Receptor 2 (TNFR2), as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors
Sponsor Bioinvent International AB
- Start (EU)
- Latest update
- Estimated end
Operational learnings available3 trial-level findings · Read insights
- The trial was conducted at 12 centers in Europe and the United States, of which 8 centers enrolled participants.
- Forty-two participants were screened by 9 sites, and 35 participants were enrolled over approximately 16 months.
- The planned Phase 2a part was not initiated.
These findings describe the trial, not the service provider’s performance or responsibility.
A prospective, randomized, double-blind, placebo-controlled, two-stage, multicenter study with an open-label extension period to investigate the efficacy and safety of NT 201 in the treatment of lower limb spasticity in children and adolescents with cerebral palsy
Sponsor Merz Pharmaceuticals GmbH
- Start (EU)
- Latest update
- Estimated end
Operational learnings available1 trial-level finding · Read insights
- Subjects were recruited at 10 investigative sites in Poland, Ukraine, and Türkiye.
These findings describe the trial, not the service provider’s performance or responsibility.
Proof-of-Concept Evaluation of Immunological Assays Using Human Blood and Urine Samples after Vaccination with StroVac
Sponsor Strathmann GmbH & Co. KG
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
Double-blind placebo-controlled clinical trial (Phase 1b/2a) to evaluate safety and efficacy of IM-250 administration in patients with recurrent genital herpes.
Sponsor Innovative Molecules GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
Adaptive, Phase 2/3, Randomized, Double-Blind Trial Investigating the Efficacy and Safety of Visugromab versus Placebo in Patients with Cancer-associated Cachexia
Sponsor CatalYm GmbH
- Start (EU)
- Latest update
- Estimated end
A Phase 3, randomized, parallel-group, double-blind, multicenter study investigating the safety and efficacy of NT 201 compared with placebo in adult participants with moderate to severe platysma prominence in Europe
Sponsor Merz Aesthetics GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
A phase 1/2a, first-in-human, open-label, multicenter, dose escalation study of MP0533 in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)
Sponsor Molecular Partners AG
- Start (EU)
- Latest update
- Estimated end
A Phase 2b, Randomized, Blinded Trial Investigating the Efficacy and Safety of Visugromab in combination with Nivolumab and Lenvatinib compared to Double Placebo and Lenvatinib in Participants with Unresectable or Metastatic Hepatocellular Carcinoma and Compensated Liver Function (Child-Pugh A) after Failure of First-Line Treatment that Included an Anti-PD-(L)1 Compound (GDFATHER-HCC-01)
Sponsor CatalYm GmbH
- Start (EU)
- Latest update
- Estimated end
P2-IMU-838-PMS - Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients with Progressive Multiple Sclerosis (Calliper)
Sponsor Immunic AG
- Start (EU)
- Latest update
- Estimated end
A long-term, double-blind, randomised, placebo-controlled clinical trial to investigate the efficacy and safety of PQ Grass 27600 SU in children and adolescents with seasonal allergic rhinitis/rhinoconjunctivitis induced by grass pollen exposure
Sponsor Allergy Therapeutics (UK) Limited
- Start (EU)
- Latest update
- Estimated end
A parallel-group treatment, proof-of-concept Phase 2, multicenter, double-blind, randomized two-arm clinical trial to investigate the efficacy and safety of subcutaneous NT 201 injections compared with placebo injections in decreasing pain intensity in male and female participants aged 18 years and older with moderate to severe chronic peripheral neuropathic pain due to postherpetic neuralgia or peripheral nerve injury.
Sponsor Merz Therapeutics GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
Operational learnings available3 trial-level findings · Read insights
- Participants were recruited at 26 sites in Bulgaria, France, Germany, Hungary, Poland, and Spain.
- A protocol amendment specified adjustment of primary and secondary efficacy analyses for painful skin surface area as a potential confounder or modifier because it was proportional to planned injection points.
- A subsequent protocol amendment reduced the maximum NT 201 dose to 300 U, added pulmonary function tests, adapted the visit schedule, and simplified eCOA data collection.
These findings describe the trial, not the service provider’s performance or responsibility.
A Phase III, multisite, randomized, double-blind trial of BNT327 in combination with chemotherapy versus placebo with chemotherapy in patients with previously untreated locally recurrent inoperable or metastatic TNBC determined ineligible for PD(L)1 therapy based on PD-L1 negative disease
Sponsor BioNTech SE
- Start (EU)
- Latest update
- Estimated end
Prospective, randomized, double-blind, placebo-controlled, multicenter study to investigate the efficacy and safety of NT 201 in the treatment of lower limb spasticity caused by stroke or traumatic brain injury in adult subjects, followed by an open label extension with or without combined upper limb treatment
Sponsor Merz Pharmaceuticals GmbH
- Start (EU)
- Latest update
- Estimated end
A prospective, multicenter, open-label, randomized, actively controlled, parallel-group Phase 3 clinical trial to evaluate efficacy, safety, and tolerability of IMA203 versus investigator’s choice of treatment in patients with previously treated, unresectable or metastatic cutaneous melanoma (ACTengine® IMA203-301)
Sponsor Immatics US Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase III, Randomized, Open-label Trial of BNT324 Versus Docetaxel With Prednisone/Prednisolone in Metastatic Castration-resistant Prostate Cancer
Sponsor BioNTech SE
- Start (EU)
- Not reported
- Latest update
- Estimated end
Phase 3, double-blind, placebo-controlled, multicentre study on the efficacy and safety of human plasma derived antithrombin (Atenativ) in heparin-resistant patients scheduled to undergo cardiac surgery necessitating cardiopulmonary bypass
Sponsor Octapharma AG
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Randomized, Blinded, Placebo-Controlled Trial Investigating the Efficacy and Safety of Visugromab plus Nivolumab with or without Docetaxel versus Docetaxel Monotherapy in Second-Line Treatment of Participants with Metastatic Non-Squamous Non-Small Cell Lung Cancer (GDFATHER-NSCLC-02)
Sponsor CatalYm GmbH
- Start (EU)
- Latest update
- Estimated end
A Phase III Multicenter, Randomized, Double-Blind, Double-Dummy Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison with Fingolimod in Children and Adolescents with Relapsing-Remitting Multiple Sclerosis
Sponsor F. Hoffmann-La Roche AG
- Start (EU)
- Latest update
- Estimated end
A global multicenter phase 1/2 trial of EO2463, a novel microbial-derived peptide therapeutic vaccine, as monotherapy, and in combination with lenalidomide and rituximab, for treatment of patients with indolent Non-Hodgkin's Lymphoma.
Sponsor Enterome
- Start (EU)
- Latest update
- Estimated end
A multi-center Phase 2 study of neoadjuvant immunotherapy in combination with the anti-GDF-15 antibody visugromab (CTL-002) for the treatment of muscle invasive bladder cancer
Sponsor CatalYm GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Metronomia Clinical Research?
The 2026-10-09 snapshot links Metronomia Clinical Research to 29 distinct CTIS trials. Recorded services include Statistical analysis, Data management, Electronic data capture, Medical writing, among 11 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Metronomia Clinical Research?
The most frequently recorded therapeutic areas are Solid Tumor Oncology, Neurology, Respiratory, Dermatology. Recorded phases include Phase 2, Phase 3, Phase 1, Phase 4. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Metronomia Clinical Research conducted?
The linked trials record locations in 24 countries, including Germany, Spain, Poland, France, Italy. These are trial locations, not confirmed office locations or countries where Metronomia Clinical Research delivered services.
What can this page tell me about Metronomia Clinical Research's trial experience?
Browse 29 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 3 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Metronomia Clinical Research. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Metronomia Clinical Research GmbH